RedHill Biopharma announces positive top-line results from Phase III study of RHB-104 in Crohn's Disease; remission rates at week-52 are low by market comparison; Redhill plans to raise additional capital to support future clinical development; target price remains at NIS 2.59 TEL...
from PR Newswire: //https://ift.tt/2LPwugk
No comments:
Post a Comment